Related Experiment Video
Updated: Mar 7, 2026
10:46
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
4.5K
Smac Mimetics to Therapeutically Target IAP Proteins in Cancer.
1Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Frankfurt, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.
International Review of Cell and Molecular Biology
|February 21, 2017
Summary
Smac mimetics are novel cancer therapeutics targeting Inhibitor of Apoptosis (IAP) proteins. These drugs mimic the Smac protein, showing potential in preclinical studies to induce cancer cell death and are now in early clinical trials.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Inhibitor of Apoptosis (IAP) proteins are frequently overexpressed in human cancers.
- Overexpressed IAPs contribute to cancer cell survival and resistance to apoptosis.
- IAPs represent promising therapeutic targets for cancer treatment.
Purpose of the Study:
- To review the therapeutic potential of Smac mimetics in targeting IAP proteins for cancer therapy.
- To summarize the mechanism of action of Smac mimetics.
- To discuss the current clinical development status of Smac mimetics.
Main Methods:
- Literature review of preclinical and clinical studies on Smac mimetics.
- Analysis of the role of IAP proteins in cancer.
- Examination of the mechanism by which Smac mimetics antagonize IAPs.
Main Results:
- Smac mimetics mimic the endogenous Smac protein, antagonizing IAPs.
- Preclinical studies demonstrate Smac mimetics can induce cancer cell death or sensitize cells to other death-inducing agents.
- Several Smac mimetics are currently undergoing evaluation in early-phase clinical trials.
Conclusions:
- Smac mimetics hold significant promise as a novel class of cancer therapeutics.
- Targeting IAP proteins with Smac mimetics offers a potential strategy to overcome cancer resistance.
- Further clinical investigation is warranted to establish the efficacy and safety of Smac mimetics in cancer patients.
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:23Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
03:03mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
01:31The Intrinsic Apoptotic Pathway
9.0K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K
02:53Adaptive Mechanisms in Cancer Cells
7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K